RCEL
AVITA Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$11.20
+2.38%Aug 18, 2026, 11:45 UTC
AVITA Medical announced positive study results for its PermeaDerm product, demonstrating a 70% economic advantage over allograft and comparable clinical outcomes.
Aug 7, 2026, 06:54 UTC
AVITA Medical, Inc. held its Q2 2026 earnings call on August 6, 2026.
Jun 8, 2026, 00:00 UTC
AVITA Medical issued a warrant to Perceptive Credit Holdings V, LP as part of a credit agreement, granting rights to purchase up to 500,000 shares of common stock.